Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) Verified in Norway

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1057-1061

  Unemo, Magnus ^a   Golparian, Daniel ^a,b   Skogen, Vegard ^c   Olsen, Anne Olaug ^a,d,e   Moi, Harald ^e   Syversen, Gaute ^d   Hjelmevoll, Stig Ove ^b  

^a Swedish Reference Laboratory for Pathogenic Neisseria   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CEFTRIAXONE; RIBOSOMAL PROTEIN S5; RIBOSOME PROTEIN; RNA 16S; SPECTINOMYCIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; CODON; GENE DELETION; GENETIC RESISTANCE; GONORRHEA; HUMAN; MALE; NEISSERIA GONORRHOEAE; NONHUMAN; NORWAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, BACTERIAL; GONORRHEA; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEISSERIA GONORRHOEAE; NORWAY; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 16S; SEQUENCE ALIGNMENT; SPECTINOMYCIN;

EID: 84872862875     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01775-12     Document Type: Article

References (53)

1. Bolan GA, Sparling PF, Wasserheit JN. 2012. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 366:485-487.
2. Lewis DA. 2010. The gonococcus fights back: Is this time a knock out? Sex. Transm. Infect. 86:415-421.
3. Stoltey JE, Barry PM. 2012. The use of cephalosporins for gonorrhea: An update on the rising problem of resistance. Expert Opin. Pharmacother. 13:1411-1420.
4. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7:821-834.
5. Unemo M, Shafer WM. 2011. Antibiotic resistance in Neisseria gonorrhoeae: Origin, evolution, and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230(1):E19-E28.
6. Deguchi T, Yasuda M, Yokoi S, Ishida K, Ito M, Ishihara S, Minamidate K, Harada Y, Tei K, Kojima K, Tamaki M, Maeda S. 2003. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J. Infect. Chemother. 9:35-39.
7. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 16(14):pii-19833. http://www.eurosurveillance.org/ViewArticle .aspx?ArticleId-19833.
8. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545.
9. Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D. 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58(Part 5):683-687.
10. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16(6):pii-19792. http://www .eurosurveillance.org/ ViewArticle.aspx?ArticleId-19792.
11. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. 2012. High-level cefixime-and ceftriaxone-resistant N. gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56:1273-1280.
12. Unemo M, Golparian D, Potocnik M, Jeverica S. 2012. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill. 17(25): Pii-20200. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-20200.
13. Unemo M, Golparian D, Stary A, Eigentler A. 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 16(43):pii-19998. http: //www.eurosurveillance.org/ViewArticle.aspx?ArticleId-19998.
14. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended firstline cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 15(47):pii-19721. http://www.eurosurveillance.org/ViewArticle.aspx ?ArticleId-19721.
15. Whiley DM, Goire N, Lahra MM, Donovan B, Limnios AE, Nissen MD, Sloots TP. 2012. The ticking time bomb: Escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J. Antimicrob. Chemother. 67:2059-2061.
16. Chisholm SA, Quaye N, Cole MJ, Fredlund H, Hoffmann S, Jensen JS, van de Laar MJ, Unemo M, Ison CA. 2011. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J. Antimicrob. Chemother. 66:592-595.
17. Dowell D, Kirkcaldy RD. 23 August 2012, posting date. Effectiveness of gentamicin for gonorrhoea treatment: Systematic review and metaanalysis. Sex. Transm. Infect. [Epub ahead of print.] doi:10.1136/sextrans-2012-050604.
18. Ross JD, Lewis DA. 2012. Cephalosporin resistant Neisseria gonorrhoeae: Time to consider gentamicin? Sex. Transm. Infect. 88:6-8.
19. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. 2012. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: Potential treatment option for gonorrhea? Antimicrob. Agents Chemother. 56:2739-2742.
20. Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, Tapsall JW. 2012. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: Ertapenem for treatment of gonorrhea? Antimicrob. Agents Chemother. 56:3603-3609.
21. Bignell C, Fitzgerald M, Guideline Development Group, British Association for Sexual Health and HIV UK. 2011. UK national guideline for the management of gonorrhoea in adults, 2011. Int. J. STD AIDS 22:541-547.
22. Moran JS. 1995. Treating uncomplicated Neisseria gonorrhoeae infections: Is the anatomic site of infection important? Sex. Transm. Dis. 22:39-47.
23. Moran JS, Levine WC. 1995. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin. Infect. Dis. 20(Suppl 1):S47-S65.
24. Newman LM, Moran JS, Workowski KA. 2007. Update on the management of gonorrhea in adults in the United States. Clin. Infect. Dis. 44(Suppl 3):S84-S101.
25. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 59(RR-12):1-110.
26. Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ. 2011. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill. 16(42):pii-19995. http://www .eurosurveillance.org/ViewArticle.aspx? ArticleId-19995.
27. European Centre for Disease Prevention and Control (ECDC). 2012. Gonococcal antimicrobial susceptibility surveillance in Europe, 2010. ECDC, Stockholm, Sweden. http://ecdc.europa.eu/en/publications /Publications/1206- Gonococcal-AMR.pdf. Accessed 30 October 2012.
28. Anonymous. 2006. Discontinuation of spectinomycin. MMWR 55:370.
29. Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, Khan WN, Stein DC. 1987. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and penicillinase-producing Neisseria gonorrhoeae. N. Engl. J. Med. 317:272-278.
30. Bilgin N, Richter AA, Ehrenberg M, Dahlberg AE, Kurland CG. 1990. Ribosomal RNA and protein mutants resistant to spectinomycin. EMBO J. 9:735-739.
31. Ramakrishnan V, White SW. 1992. The structure of ribosomal protein S5 reveals sites of interaction with 16S rRNA. Nature 358:768-771.
32. Moazed D, Noller HF. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389-394.
33. Sigmund CD, Ettayebi M, Morgan EA. 1984. Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res. 12:4653-4663.
34. Binet R, Maurelli AT. 2005. Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC. Antimicrob. Agents Chemother. 49:4455-4464.
35. Brink MF, Brink G, Verbeet MP, de Boer HA. 1994. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 22:325-331.
36. Criswell D, Tobiason VL, Lodmell JS, Samuels DS. 2006. Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 50:445-452.
37. Davies C, Bussiere DE, Golden BL, Porter SJ, Ramakrishnan V, White SW. 1998. Ribosomal proteins S5 and L6: High resolution crystal structures and roles in protein biosynthesis and antibiotic resistance. J. Mol. Biol. 279:873-888.
38. Funatsu G, Schiltz E, Wittmann HG. 1971. Ribosomal proteins. XXVII. Localization of the amino acid exchanges in protein S5 from two Escherichia coli mutants resistant to spectinomycin. Mol. Gen. Genet. 114:106-111.
39. Galimand M, Gerbaud G, Courvalin P. 2000. Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrob. Agents Chemother. 44:1365-1366.
40. Johanson U, Hughes D. 1995. A new mutation in 16S rRNA of Escherichia coli conferring spectinomycin resistance. Nucleic Acids Res. 23:464-466.
41. Kehrenberg C, Catry B, Haesebrouck F, de Kruif A, Schwarz S. 2005. Novel spectinomycin/streptomycin resistance gene, aadA14, from Pasteurella multocida. Antimicrob. Agents Chemother. 49:3046-3049.
42. Kehrenberg C, Schwarz S. 2007. Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida. Antimicrob. Agents Chemother. 51:2244-2246.
43. Kirthi N, Roy-Chaudhuri B, Kelley T, Culver GM. 2006. A novel single amino acid change in small subunit ribosomal protein S5 has profound effects on translational fidelity. RNA 12:2080-2091.
44. LeBlanc DJ, Lee LN, Inamine JM. 1991. Cloning and nucleotide base sequence analysis of a spectinomycin adenyltransferase AAD(9) determinant from Enterococcus faecalis. Antimicrob. Agents Chemother. 35: 1804-1810.
45. Makosky PC, Dahlberg AE. 1987. Spectinomycin resistance at site 1192 in 16S ribosomal RNA of E. coli: An analysis of three mutants. Biochimie 69:885-889.
46. Murphy E. 1985. Nucleotide sequence of a spectinomycin adenyltransferase AAD(9) determinant from Staphylococcus aureus and its relationship to AAD(3-) (9). Mol. Gen. Genet. 200:33-39.
47. O'Connor M, Dahlberg AE. 2002. Isolation of spectinomycin resistance mutations in the 16S rRNA of Salmonella enterica serovar Typhimurium and expression in Escherichia coli and Salmonella. Curr. Microbiol. 45: 429-433.
48. Suter TM, Viswanathan VK, Cianciotto NP. 1997. Isolation of a gene encoding a novel spectinomycin phosphotransferase from Legionella pneumophila. Antimicrob. Agents Chemother. 41:1385-1388.
49. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall JW. 2009. Phenotypic and genetic characterization of the 2008WHONeisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151.
50. Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Unemo M, Skogen V. 2006. A fast real-time polymerase chain reaction method for sensitive and specific detection of the Neisseria gonorrhoeae porA pseudogene. J. Mol. Diagn. 8:574-581.
51. Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Melby KK, Moi H, Unemo M, Skogen V. 2008. Clinical validation of a real-time polymerase chain reaction detection of Neisseria gonorrheae porA pseudogene versus culture techniques. Sex. Transm. Dis. 35:517-520.
52. Ohnishi M, Watanabe Y, Ono E, Takahashi C, Oya H, Kuroki T, Shimuta K, Okazaki N, Nakayama S, Watanabe H. 2010. Spreading of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob. Agents Chemother. 54:1060-1067.
53. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J. Antimicrob. Chemother. 67:1858-1860.